Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1980 1
1983 1
1985 1
1994 2
1996 1
1999 1
2001 1
2008 2
2009 1
2011 1
2013 1
2014 4
2015 2
2016 1
2018 4
2020 3
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D; ELIPSE HoFH Investigators. Raal FJ, et al. N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215. N Engl J Med. 2020. PMID: 32813947 Clinical Trial.
Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with hom …
Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against …
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency.
Arca M, D'Erasmo L, Minicocci I. Arca M, et al. Curr Opin Lipidol. 2020 Apr;31(2):41-48. doi: 10.1097/MOL.0000000000000668. Curr Opin Lipidol. 2020. PMID: 32022755 Review.
RECENT FINDINGS: Experimental studies have further illustrated the complex interplay between ANGPTL3 and ANGPTL4-8 in orchestrating lipid transport in different nutritional status. Individuals with familial combined hypolipidemia due to homozygous loss-of-function mutation …
RECENT FINDINGS: Experimental studies have further illustrated the complex interplay between ANGPTL3 and ANGPTL4-8 in orchestrating lipid tr …
Healthy Uses for Garlic.
White D. White D. Nurs Clin North Am. 2021 Mar;56(1):153-156. doi: 10.1016/j.cnur.2020.12.001. Nurs Clin North Am. 2021. PMID: 33549282 Review.
Update on primary hypobetalipoproteinemia.
Hooper AJ, Burnett JR. Hooper AJ, et al. Curr Atheroscler Rep. 2014 Jul;16(7):423. doi: 10.1007/s11883-014-0423-3. Curr Atheroscler Rep. 2014. PMID: 24781598 Free article. Review.
Abetalipoproteinemia and homozygous familial hypobetalipoproteinemia, although caused by mutations in different genes, are clinically indistinguishable. A framework for the clinical follow-up and management of these two disorders has been proposed recently, focusing on mon …
Abetalipoproteinemia and homozygous familial hypobetalipoproteinemia, although caused by mutations in different genes, are clinically indist …
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.
Welty FK. Welty FK. Curr Opin Lipidol. 2020 Apr;31(2):49-55. doi: 10.1097/MOL.0000000000000663. Curr Opin Lipidol. 2020. PMID: 32039990 Review.
Mutations in the angiopoietin-like protein 3 ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). Clinical manifestations range from none-to-severe, debilitating and life-threatening disorders. This review summarizes recent genetic, metabolic and clinical …
Mutations in the angiopoietin-like protein 3 ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). Clinical manifestatio …
Effects of alpha lipoic acid on metabolic syndrome: A comprehensive review.
Najafi N, Mehri S, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Najafi N, et al. Phytother Res. 2022 Jun;36(6):2300-2323. doi: 10.1002/ptr.7406. Epub 2022 Mar 2. Phytother Res. 2022. PMID: 35234312 Review.
Alpha-lipoic acid (alpha-LA) possesses various pharmacological effects, including antidiabetic, antiobesity, hypotensive, and hypolipidemia actions. It exhibits reactive oxygen species scavenger properties against oxidation and age-related inflammation and refines MetS com …
Alpha-lipoic acid (alpha-LA) possesses various pharmacological effects, including antidiabetic, antiobesity, hypotensive, and hypolipidem …
Supplementation with food-derived oligopeptides promotes lipid metabolism in young male cyclists: a randomized controlled crossover trial.
Jin A, Kan Z, Tan Q, Shao J, Han Q, Chang Y, An N, Yi M. Jin A, et al. J Int Soc Sports Nutr. 2023 Dec;20(1):2254741. doi: 10.1080/15502783.2023.2254741. J Int Soc Sports Nutr. 2023. PMID: 37674290 Free PMC article. Clinical Trial.
However, whether supplementation with oligopeptides derived from multiple food sources can promote lipid degradation and fat oxidation in athletes remains unclear. Therefore, in a randomized controlled crossover trial, we investigated the impact of food-derived olig …
However, whether supplementation with oligopeptides derived from multiple food sources can promote lipid degradation and fat oxidation in at …
Metabolic alterations and hepatitis C: From bench to bedside.
Chang ML. Chang ML. World J Gastroenterol. 2016 Jan 28;22(4):1461-76. doi: 10.3748/wjg.v22.i4.1461. World J Gastroenterol. 2016. PMID: 26819514 Free PMC article. Review.
In addition to causing cirrhosis and hepatocellular carcinoma, hepatitis C virus (HCV) is thought to cause hypolipidemia, hepatic steatosis, insulin resistance, metabolic syndrome, and diabetes. ...
In addition to causing cirrhosis and hepatocellular carcinoma, hepatitis C virus (HCV) is thought to cause hypolipidemia, hepatic ste …
The role of fibric acids in atherosclerosis.
Fruchart JC, Staels B, Duriez P. Fruchart JC, et al. Curr Atheroscler Rep. 2001 Jan;3(1):83-92. doi: 10.1007/s11883-001-0015-x. Curr Atheroscler Rep. 2001. PMID: 11123853 Review.
Some fibric acid molecules are active in essential hypercholesterolemia. Clinical evidence shows that fibric acids reduce coronary atherosclerosis progression in dyslipidemic patients (eg, bezafibrate, gemfibrozil) and in type 2 diabetic patients (fenofibrate). Gemfibrozil …
Some fibric acid molecules are active in essential hypercholesterolemia. Clinical evidence shows that fibric acids reduce coronary at …
29 results